Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
Antonia Martinetti(Cochlear (Australia)), Emilio Bombardieri(Humanitas Gavazzeni), Luisa Toffolatti(Fondazione IRCCS Istituto Nazionale dei Tumori), Ignazia La Torre(Hospital Universitari i Politècnic La Fe), Emilio Bajetta(Fondazione Lanza), Luca Ferrari(Roche (Switzerland)), Ettore Seregni(Fondazione IRCCS Istituto Nazionale dei Tumori), D Paleari(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), R. Longarini(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicoletta Zilembo(ANT Foundation Italy Onlus)
Cited by 32
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k